真实世界抗糖尿病药物使用与12,277例2型糖尿病患者骨折风险:一项巢式病例对照研究
在加泰罗尼亚SIDIAP数据库中2006-2012年新诊断2型糖尿病患者队列内开展巢式病例对照研究,分析12,277例患者(2049例骨折病例与10,228例对照)。与二甲双胍单药治疗相比,胰岛素治疗与骨折风险升高相关(校正OR 1.63,95%CI 1.30-2.04),二甲双胍联合磺脲类亦然(校正OR 1.29,95%CI 1.07-1.56)。敏感性分析提示胰岛素治疗可能存在因果关系,而二甲双胍联合磺脲类的关联则不然。
要点
- 与二甲双胍单药相比,胰岛素治疗与骨折风险升高相关(校正OR 1.63,95%CI 1.30-2.04)。
- 与二甲双胍单药相比,二甲双胍联合磺脲类与骨折风险升高相关(校正OR 1.29,95%CI 1.07-1.56)。
- 其他抗糖尿病药物未发现显著关联。
核心结论
- 在2型糖尿病患者中,与二甲双胍单药治疗相比,胰岛素单药治疗与骨折风险升高相关。
- 开始降糖药物治疗作为2型糖尿病治疗的一部分时,应考虑骨折风险。
研究设计与样本
- 每例病例(新发主要骨质疏松性骨折)按2型糖尿病诊断日历年及出生年份(±10年)与最多5名同性别对照进行风险集匹配。
- 研究暴露为索引日期前6个月内 dispensed 的所有抗糖尿病药物(单药或联合)既往使用,以二甲双胍单药治疗(最常用药物)为参考组(活性对照)。
- 共分析12,277例2型糖尿病患者数据(2049例病例和10,228例对照)。
主要发现
- 与二甲双胍单药治疗相比,胰岛素使用与骨折风险升高相关(校正OR 1.63,95%CI 1.30-2.04)。
- 与二甲双胍单药治疗相比,二甲双胍联合磺脲类与骨折风险升高相关(校正OR 1.29,95%CI 1.07-1.56)。
- 敏感性分析提示胰岛素治疗可能存在因果关系,但二甲双胍联合磺脲类的关联则不然。
- 未发现与其他任何抗糖尿病药物有显著关联。
临床怎么用
- 作者认为,在开始降糖药物治疗作为2型糖尿病治疗的一部分时,应考虑骨折风险。
局限性
- 敏感性分析提示胰岛素治疗可能存在因果关系,但二甲双胍联合磺脲类的关联则不然。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: We conducted a nested case-control study to study the association between antidiabetic treatments (alone or in combination) use and fracture risk among incident type 2 Diabetes mellitus patients. We found an increased risk of bone fracture with insulin therapy compared to metformin monotherapy. INTRODUCTION: Patients with type 2 diabetes mellitus (T2DM) have an increased risk of fragility fractures, to which antidiabetic therapies may contribute. We aimed to characterize the risk of fracture associated with different antidiabetic treatments as usually prescribed to T2DM patients in actual practice conditions. METHODS: A case-control study was nested within a cohort of incident T2DM patients registered in 2006-2012 in the Information System for Research Development in Primary Care (Catalan acronym, SIDIAP), a database which includes records for > 5.5 million patients in Catalonia (Spain). Each case (incident major osteoporotic fracture) was risk-set matched with up to five same-sex controls by calendar year of T2DM diagnosis and year of birth (± 10 years). Study exposure included previous use of all antidiabetic medications (alone or in combination), as dispensed in the 6 months before the index date, with metformin (MTF) monotherapy, the most commonly used drug, as a reference group (active comparator). RESULTS: Data on 12,277 T2DM patients (2049 cases and 10,228 controls) were analyzed. Insulin use was associated with increased fracture risk (adjusted OR 1.63 (95% CI 1.30-2.04)), as was the combination of MTF and sulfonylurea (SU) (adjusted OR 1.29 (1.07-1.56)), compared with MTF monotherapy. Sensitivity analyses suggest possible causality for insulin therapy but not for the MTF + SU combination association. No significant association was found with any other antidiabetic medications. CONCLUSIONS: Insulin monotherapy was associated with an increased fracture risk compared to MTF monotherapy in T2DM patients. Fracture risk should be taken into account when starting a glucose-lowering drug as part of T2DM treatment.
引用
- Losada E, Soldevila B, Ali MS, et al. Real-world antidiabetic drug use and fracture risk in 12,277 patients with type 2 diabetes mellitus: a nested case-control study. Osteoporos Int. 2018. PMID: 29860664. doi:10.1007/s00198-018-4581-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。